PhaseBio Pharmaceuticals, Inc. (PHAS)
CapEx to Revenue
27.88%
Quarterly · Period ending:
PHAS CapEx to Revenue
Latest reported27.88%period ending
Latest reported27.88%period ending
PHAS Quarterly CapEx/Revenue (0.00% → 27.88%)
Latest values, visible window
High-resolution chart · PNG
PHAS capex to revenue history
Quarterly. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | CapEx to Revenue |
|---|---|
| 27.8846% | |
| 41.8803% | |
| 1,048.1013% | |
| 190.4478% | |
| 2.4376% | |
| 0% | |
| 17,187,500,000,000% | |
| 73.8589% | |
| 74.111% | |
| 205.625% | |
| 17.801% | |
| 163.9004% | |
| 49.0754% | |
| 12.8637% | |
| 34.2412% | |
| 0.7299% | |
| 0% | |
| 0% | |
| 0% | |
| 0% |